Biodesix Inc Stock News

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Execut

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced its financial and operatin

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus on lung disease, announced today that it will release finan

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data will be pres

Tap four stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include OI Glass (OI), KE Hodlings (BEKE), Biodesix (BDSX) and Phunware (PHUN).

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton,

Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.40 per share a year ago.

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, announced today that it will r

Biodesix, Inc. (NASDAQ:BDSX ) Q1 2023 Earnings Conference Call May 11, 2023 6:00 PM ET Company Participants Chris Brinzey - Investor Relations Scott Hutton - Chief Executive Officer Robin Harper Cowie

Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.50 per share a year ago.

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, announced today that it will r

Biodesix, Inc. (NASDAQ:BDSX ) Q4 2022 Earnings Conference Call March 6, 2023 8:00 AM ET Company Participants Chris Brinzey - Investor Relations Scott Hutton - Chief Executive Officer Robin Harper Cowi

Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of -7.69% and 10.23%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, announced today that it will r

Biodesix, Inc. published its Q3 financial results on November 3, 2022. The firm provides an array of lung cancer diagnostic tests in the U.S.